Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells-Reference-Cited by-同舟云学术

Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells

Published:2022 Issue:3 Volume:62 Page:147-153
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Ohno Sayaka¹,Hayashi Kiyohito¹,Shimizu Ryo¹,Ishii Akihiro²,Tanaka Hiroaki¹

Affiliation:

1. Department of Hematology, Asahi General Hospital, Chiba, Japan,

2. Department of Transfusion Medicine, Asahi General Hospital, Chiba, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/62/3/62_22013/_pdf

Reference13 articles.

1. 1 Fricker SP. Physiology and pharmacology of plerixafor. Transfus Med Hemother. 2013; 40: 237-245.

2. 2 DiPersio JF, Micallef IN, Stiff PJ et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009; 27: 4767-4773.

3. 3 DiPersio JF, Stadtmauer EA, Nademanee A et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113: 5720-5726.

4. 4 Yiğenoğlu TN, Başcı S, Ulu BU et al. Inferior prognosis in poor mobilizing myeloma patients. Transfus Apheresis Sci. 2020; 59: 102722.

5. 5 Niesvizky R, Mark TM, Ward M et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res. 2013; 19: 1534-1546.